BioMarin Pharmaceutical (BMRN) Earnings Expected to Grow: Should You Buy?
BioMarin (BMRN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BMRN - BioMarin Pharmaceutical Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$90.94
DETAILS
HIGH:
$122.00
LOW:
$59.00
MEDIAN:
$90.00
CONSENSUS:
$90.94
UPSIDE:
64.72%
Stock News
BioMarin Pharmaceutical Inc. $BMRN Stock: Assenagon Asset Management S.A. Lowers Position
Assenagon Asset Management S.A. trimmed its position in shares of BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) by 24.0% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 1,339,560 shares of the biotechnology company's stock after selling 422,526 shares during
Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Value Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Financial Review: Relay Therapeutics (NASDAQ:RLAY) & BioMarin Pharmaceutical (NASDAQ:BMRN)
Relay Therapeutics (NASDAQ: RLAY - Get Free Report) and BioMarin Pharmaceutical (NASDAQ: BMRN - Get Free Report) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, earnings, valuation, dividends, institutional ownership, profitability and risk. Analyst Recommendations This is a summary of recent
BioMarin Presents New Data Advancing Understanding of Achondroplasia and Hypochondroplasia Treatment at the American Society for Bone and Mineral Research Annual Meeting
New analysis showcases impact of VOXZOGO® (vosoritide) in foramen magnum and craniocervical junction growth in children with achondroplasia, including infants SAN RAFAEL, Calif., Oct. 9, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced it will present new data from 13 studies at the American Society for Bone and Mineral Research 2026 Annual Meeting (ASBMR) in Boston, including results from studies of VOXZOGO® (vosoritide) in children with achondroplasia and hypochondroplasia.
FDA Grants Priority Review to BridgeBio's Dwarfism Drug Filing
BBIO wins FDA priority review for infigratinib, potentially making it the first approved oral therapy for achondroplasia.
BioMarin Appoints Cara Bauer as Chief People Officer
Ms. Bauer Brings More Than 25 Years of Experience in Human Resources, Across Biotechnology and Technology Industries Appointment Effective Oct. 5, 2026 SAN RAFAEL, Calif., Oct. 5, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced today that Cara Bauer, Ph.D.
BioMarin reports five-year Pompe disease data showing durable motor function
A BioMarin combination therapy helped adults with late-onset Pompe disease maintain walking distance over five years of continuous therapy. Respiratory function remained relatively stable, with no new safety signals identified.
BioMarin Announces Five-Year Phase 3 Data for POMBILITI® (cipaglucosidase alfa-atga) + OPFOLDA® (miglustat) at World Muscle Society Annual Congress
Long-term data reinforce durable efficacy and safety of POMBILITI + OPFOLDA in late-onset Pompe disease SAN RAFAEL, Calif., Oct. 2, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced new data evaluating the efficacy and safety of POMBILITI® (cipaglucosidase alfa-atga) + OPFOLDA® (miglustat) in late-onset Pompe disease (LOPD) were presented at the 31st Annual Congress of the World Muscle Society (WMS), in Hiroshima, Japan.
Profluent Partners With BioMarin to Design Novel Medicines Using AI
EMERYVILLE, Calif.--(BUSINESS WIRE)---- $BMRN--Profluent, the frontier AI lab for biology, today announced a collaboration with BioMarin Pharmaceutical Inc. to design and optimize novel enzyme therapies for BioMarin's pipeline. Under the agreement, Profluent will apply its foundational AI models to generate novel potential drug candidates, and BioMarin will screen the results with the goal to eventually advance the most promising designs. Developing and optimizing therapeutic enzymes is a complex process.
Reviewing Metagenomi (NASDAQ:MGX) and BioMarin Pharmaceutical (NASDAQ:BMRN)
BioMarin Pharmaceutical (NASDAQ: BMRN - Get Free Report) and Metagenomi (NASDAQ: MGX - Get Free Report) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, profitability, institutional ownership, dividends, earnings, analyst recommendations and valuation. Earnings and Valuation This table compares BioMarin Pharmaceutical and
BioMarin: Why I See Significant Upside Into 2027
Q4 2026/ 2027 will be rich in catalysts for BioMarin Pharmaceutical Inc. From the presentation of 12 mg/kg BMN 351 Phase 1/2 data in Duchenne muscular dystrophy by year-end 2026 to a potential H1 2027 approval of Voxzogo for hypochondroplasia. BioMarin raised its full-year 2026 revenue guidance from $3.83 billion-$3.93 billion to $3.88 billion-$3.93 billion.
BioMarin Targets Amicus Synergies as VOXZOGO Nears $1B Milestone
BioMarin Pharmaceutical NASDAQ: BMRN said it is progressing with the integration of Amicus Therapeutics while pursuing additional business-development opportunities, as executives outlined growth plans for newly acquired rare-disease products, VOXZOGO and several pipeline programs at Morgan Stanley's Global Healthcare Conference.
BioMarin Stops Voxzogo Development for Noonan Syndrome
BMRN ends Voxzogo development for Noonan syndrome as the drug faces new competition and pursues other growth opportunities.
BioMarin Pharmaceutical Inc. (BMRN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
BioMarin Pharmaceutical Inc. (BMRN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
BioMarin Announces Appointment of Robert Plenge, M.D., Ph.D., Chief Research Officer of Bristol Myers Squibb, to Board of Directors
SAN RAFAEL, Calif., Sept. 14, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced that the company has appointed Robert Plenge, M.D.
BioMarin Pharmaceutical Inc. $BMRN Shares Acquired by Amundi
Amundi lifted its stake in shares of BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) by 37.8% during the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 259,782 shares of the biotechnology company's stock after acquiring an additional 71,246 shares during the period. Amundi
BioMarin Pharmaceutical Inc. (BMRN) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
BioMarin Pharmaceutical Inc. (BMRN) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
BioMarin Pharmaceutical Inc. (BMRN) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript
BioMarin Pharmaceutical Inc. (BMRN) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript
BioMarin Pharmaceutical Inc. (BMRN) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
BioMarin Pharmaceutical Inc. (BMRN) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
Price Targets
BioMarin price target lowered to $122 from $124 at Morgan Stanley
$122.00
(was $56.48)
Morgan Stanley
BioMarin price target raised to $114 from $111 at Barclays
$114.00
(was $54.38)
Barclays
BioMarin price target lowered to $97 from $98 at BMO Capital
$97.00
(was $64.60)
BMO Capital
BioMarin price target raised to $86 from $85 at Cantor Fitzgerald
$86.00
(was $65.31)
Cantor Fitzgerald
BioMarin price target raised to $90 from $88 at Piper Sandler
$90.00
(was $65.23)
Piper Sandler
BioMarin price target raised to $105 from $104 at Jefferies
$105.00
(was $65.53)
Akash Tewari
·
Jefferies
BioMarin price target raised to $109 from $105 at Raymond James
$109.00
(was $65.39)
Raymond James
Piper Sandler on BioMarin Pharmaceutical Inc. (BMRN): 'We Remain Bullish After Hosting Management Meetings'
$88.00
(was $66.10)
UBS
BioMarin initiated with an Outperform at BMO Capital
$98.00
(was $66.99)
David Lebowitz
·
BMO Capital
BioMarin price target lowered to $59 from $60 at H.C. Wainwright
$59.00
(was $67.79)
H.C. Wainwright
BioMarin price target raised to $88 from $82 at Piper Sandler
$88.00
(was $67.36)
Piper Sandler
BioMarin price target raised to $111 from $105 at Barclays
$111.00
(was $67.36)
Eliana Merle
·
Barclays
BioMarin Pharmaceutical Inc. (BMRN) PT Raised to $114 at Canaccord
$114.00
(was $63.81)
Whitney Ijem
·
Canaccord Genuity
BioMarin price target raised to $105 from $100 at Raymond James
$105.00
(was $63.80)
Raymond James
BioMarin price target raised to $124 from $119 at Morgan Stanley
$124.00
(was $63.84)
Morgan Stanley
BioMarin price target raised to $70 from $68 at Stifel
$70.00
(was $63.55)
Stifel Nicolaus
BioMarin Pharmaceutical Inc. (BMRN) PT Raised to $97 at Oppenheimer
$97.00
(was $61.46)
Leland Gershell
·
Oppenheimer
BioMarin price target lowered to $62 from $66 at RBC Capital
$62.00
(was $58.79)
Luca Issi
·
RBC Capital
BioMarin price target lowered to $111 from $116 at Canaccord
$111.00
(was $54.10)
Canaccord Genuity
BioMarin price target lowered to $62 from $64 at Leerink
$62.00
(was $49.67)
Leerink Partners